Breast Cancer, Non-metastatic   

This situation can feel uncomfortable. Would this feel safer if the patient is s/p mastectomy and had TNBC?

Would you recommend aiming for the postmenopausal range as per the lab reference range or do you have a specific goal?

Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?

Would you consider omitting treatment if small tumor and early stage? Or would you use tamoxifen?

Which agents would you select and for how long would you treat them?